Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Sjögren’s  Syndrome  and  Ankylosing   Spondylitis   Association:   A Case-Based Review

Abstract

Introduction

Unlike restrictive pulmonary function and apical fibrobullous disease, diffuse interstitial lung disease is scarce in patients with ankylosing spondylitis (AS). We present a systematic review of the association between AS and SS. We also report a new case of SS revealed by interstitial lung disease in AS patients treated with tumor necrosis factor (TNF) inhibitors.

Materials and methods

The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline using the MEDLINE and SCOPUS databases and included case reports and case series describing the association between AS and SS.

Results

There were sixty-three patients, including our case: 16 males and 47 females. The mean age was 49.2 years. The mean SpA duration was 14.1 years. The mean delay between SpA and SS was 12.8 years (0-27). SS was diagnosed after SpA in 62% of cases (n=39). It preceded SpA in 36.5% (n=23) and was concomitant with SpA in 1 case. All patients had sicca symptoms. MSGB showed focal sialadenitis grade III or grade IV in the Chisholm classification in 20 patients. Anti-nuclear antibody was positive in 75.8% of cases. Among them, anti-SSA and anti-SSB were positive in 44.4% and 35.3% of cases. Except for our patient, no patient had interstitial lung disease. SS extra glandular manifestations were reported in 12 cases.

Conclusion

The occurrence of Sjögren’s syndrome is uncommon in patients with ankylosing spondylitis. This association has been reported in the literature, suggesting a pathogenetic link between these two diseases. This association should be considered in ankylosing spondylitis patients with diffuse interstitial lung disease. Knowing this association is necessary for therapeutic adjustment.

Our study has some limitations. Publication bias was the major bias in our study. Indeed, we only included case reports and case series describing the association between SpA and SS. We did not search for unpublished work. Moreover, the follow-up was not specified in most included articles.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971315532240920065136
2024-11-05
2025-01-24

  • From This Site

    /content/journals/crr/10.2174/0115733971315532240920065136
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Zochling J. Brandt J. Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology 2005 44 12 1483 1491 10.1093/rheumatology/kei047 16091395
    [Google Scholar]
  2. Rudwaleit M. van der Heijde D. Landewé R. Akkoc N. Brandt J. Chou C.T. Dougados M. Huang F. Gu J. Kirazli Y. Van den Bosch F. Olivieri I. Roussou E. Scarpato S. Sørensen I.J. Valle-Oñate R. Weber U. Wei J. Sieper J. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 2011 70 1 25 31 10.1136/ard.2010.133645 21109520
    [Google Scholar]
  3. El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 2011 22 6 554 560 10.1016/j.ejim.2011.06.006 22075279
    [Google Scholar]
  4. Kanathur N. Lee-Chiong T. Pulmonary manifestations of ankylosing spondylitis. Clin. Chest Med. 2010 31 3 547 554 10.1016/j.ccm.2010.05.002 20692546
    [Google Scholar]
  5. Zhang L.W. Zhou P.R. Wei P. Cong X. Wu L.L. Hua H. Expression of interleukin-17 in primary Sjögren’s syndrome and the correlation with disease severity: A systematic review and meta-analysis. Scand. J. Immunol. 2018 87 4 e12649 10.1111/sji.12649 29476557
    [Google Scholar]
  6. Taams L.S. Steel K.J.A. Srenathan U. Burns L.A. Kirkham B.W. IL-17 in the immunopathogenesis of spondyloarthritis. Nat. Rev. Rheumatol. 2018 14 8 453 466 10.1038/s41584‑018‑0044‑2 30006601
    [Google Scholar]
  7. Whaley K. Chisholm D.M. Williamson J. Dick W.C. Nuki G. Buchanan W.W. Sjögren’s syndrome in psoriatic arthritis, ankylosing spondylitis and Reiter’s syndrome. Acta Rheumatol. Scand. 1971 17 1-4 105 114 10.3109/rhe1.1971.17.issue‑1‑4.16 5579064
    [Google Scholar]
  8. Clayman M.D. Reinertsen J.L. Ankylosing spondylitis with subsequent development of rheumatoid arthritis, Sjögren’s syndrome, and rheumatoid vasculitis. Arthritis Rheum. 1978 21 3 383 389 10.1002/art.1780210315 646836
    [Google Scholar]
  9. Collins P. Rogers S. Jackson J. McCARTAN B. Psoriasis, psoriatic arthritis and the possible association with Sjogren’s syndrome. Br. J. Dermatol. 1992 126 3 242 245 10.1111/j.1365‑2133.1992.tb00652.x 1554600
    [Google Scholar]
  10. Brandt J. Rudwaleit M. Eggens U. Mertz A. Distler A. Sieper J. Braun J. Increased frequency of Sjögren’s syndrome in patients with spondyloarthropathy. J. Rheumatol. 1998 25 4 718 724 9558175
    [Google Scholar]
  11. Scotto di Fazano C. Grilo R.M. Vergne P. Coyral D. Inaoui R. Bonnet C. Bertin P. Trèves R. Is the relationship between spondyloarthropathy and Sjögren’s syndrome in women coincidental? A study of 13 cases. Joint Bone Spine 2002 69 4 383 387 10.1016/S1297‑319X(02)00414‑1 12184435
    [Google Scholar]
  12. Brandt J. Maier T. Rudwaleit M. Kühl U. Hiepe F. Sieper J. Braun J. Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren’s syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. Clin. Exp. Rheumatol. 2002 20 1 80 84 11892716
    [Google Scholar]
  13. Tosun M. Karkucak M. Capkin E. Cakirbay H. Guler M. Topbas M. Coexisting ankylosing spondylitis and Sjogren’s syndrome: A case report. Rheumatol. Int. 2005 25 6 478 480 10.1007/s00296‑005‑0598‑6 15761725
    [Google Scholar]
  14. Chang H.K. Bang K.T. Lee B.H. Kim J.H. Bae K.W. Kim M.J. Kim S.K. Concurrence of Sjögren’s syndrome in a patient with Chlamydia-induced reactive arthritis; An unusual finding. Korean J. Intern. Med. 2006 21 2 116 119 10.3904/kjim.2006.21.2.116 16913441
    [Google Scholar]
  15. Kobak S. Celebi Kobak A. Kabasakal Y. Doganavsargil E. Sjögren’s syndrome in patients with ankylosing spondylitis. Clin. Rheumatol. 2006 26 2 173 175 10.1007/s10067‑006‑0255‑9 16547690
    [Google Scholar]
  16. Jarrot P.A. Arcani R. Darmon O. Roudier J. Cauchois R. Mazodier K. Jean R. Balandraud N. Kaplanski G. Axial articular manifestations in primary sjögren syndrome: Association with spondyloarthritis. J. Rheumatol. 2021 48 7 1037 1046 10.3899/jrheum.200189 32669446
    [Google Scholar]
  17. Bruzzese V Marrese C Scolieri P Pepe J. Psoriatic spondyloarthritis and Sjögren syndrome: A casual association? Reumatismo 2020 72 3 170 172 10.4081/reumatismo.2020.1287
    [Google Scholar]
  18. Zhao GW Huang LF Li D Zeng Y Ankylosing spondylitis coexists with rheumatoid arthritis and Sjögren’s syndrome: A case report with literature review. Clin. Rheumatol. 2021 40 5 2083 2086 10.1007/s10067‑020‑05350‑7
    [Google Scholar]
  19. Whittingham K. Barnes S. Gardiner C. Tools to measure quality of life and carer burden in informal carers of heart failure patients: A narrative review. Palliat. Med. 2013 27 7 596 607 10.1177/0269216313477179 23442879
    [Google Scholar]
  20. Chisholm D.M. Mason D.K. Labial salivary gland biopsy in Sjögren’s disease. J. Clin. Pathol. 1968 21 5 656 660 10.1136/jcp.21.5.656 5697370
    [Google Scholar]
  21. Voulgarelis M. Tzioufas A.G. Current aspects of pathogenesis in Sjögren’s syndrome. Ther. Adv. Musculoskelet. Dis. 2010 2 6 325 334 10.1177/1759720X10381431 22870458
    [Google Scholar]
  22. Moutsopoulos H.M. Chused T.M. Mann D.L. Klippel J.H. Fauci A.S. Frank M.M. Lawley T.J. Hamburger M.I. Sjögren’s syndrome (Sicca syndrome): Current issues. Ann. Intern. Med. 1980 92 2_Part_1 212 226 10.7326/0003‑4819‑92‑2‑212 7352730
    [Google Scholar]
  23. Slouma M. Kharrat L. Tezegdenti A. Dhahri R. Ghazouani E. Gharsallah I. Pro-inflammatory cytokines in spondyloarthritis: A case-control study. Expert Rev. Clin. Immunol. 2024 20 6 655 663 10.1080/1744666X.2024.2304080 38205504
    [Google Scholar]
  24. Slouma M. Kharrat L. Gharsallah I. Interleukin-22 and the diagnosis of axial spondyloarthritis. Int. J. Rheum. Dis. 2022 25 2 236 237 10.1111/1756‑185X.14275 34970838
    [Google Scholar]
  25. Slouma M. Kharrat L. Tezegdenti A. Metoui L. Dhahri R. Ghazouani E. Cheour E. Gharsallah I. Louzir B. Increased serum interleukin 22 levels in patients with axial spondyloarthritis. Expert Rev. Clin. Immunol. 2023 19 1 123 129 10.1080/1744666X.2023.2142563 36326666
    [Google Scholar]
  26. Moz S. Aita A. Basso D. Ramonda R. Plebani M. Punzi L. Spondyloarthritis: Matrix metalloproteinasesas biomarkers of pathogenesis and response to tumor necrosis factor (TNF) inhibitors. Int. J. Mol. Sci. 2017 18 4 830 10.3390/ijms18040830 28420081
    [Google Scholar]
  27. Rahmouni S. Slouma M. Bouzid S. Dhahri R. Litaiem N. Gharsallah I. Metoui L. Louzir B. Matrix metalloproteinases; A biomarker of disease activity and prognosis in spondyloarthritis: A narrative review. Curr. Rev. Clin. Exp. Pharmacol. 2023 18 1 31 38 10.2174/2772432817666220113112809 35049445
    [Google Scholar]
  28. Reveille J.D. Zhou X. Lee M. Weisman M.H. Yi L. Gensler L.S. Zou H. Ward M.M. Ishimori M.L. Learch T.J. He D. Rahbar M.H. Wang J. Brown M.A. HLA class I and II alleles in susceptibility to ankylosing spondylitis. Ann. Rheum. Dis. 2019 78 1 66 73 10.1136/annrheumdis‑2018‑213779 30341055
    [Google Scholar]
  29. Liu S. Zhang J. Liu M. Chen Q. Wang S. Wang D. Sun L. New-onset primary Sjögren’s syndrome following exposure to severe acute respiratory syndrome coronavirus 2: A retrospective cohort study. Rheumatol. Autoimmun. 2024 4 1 37 46 10.1002/rai2.12113
    [Google Scholar]
  30. Slouma M. Abbes M. Kharrat L. Gharsallah I. Post-COVID-19 reactive arthritis. Clin. Rheumatol. 2022 41 8 2609 2610 10.1007/s10067‑022‑06241‑9 35788920
    [Google Scholar]
  31. Slouma M. Abbes M. Mehmli T. Dhahri R. Metoui L. Gharsallah I. Louzir B. Reactive arthritis occurring after COVID-19 infection: A narrative review. Infection 2023 51 1 37 45 10.1007/s15010‑022‑01858‑z 35655110
    [Google Scholar]
  32. Slouma M. Mhemli T. Abbes M. Triki W. Dhahri R. Metoui L. Gharsallah I. Louzir B. Rheumatoid arthritis occurring after coronavirus disease 2019 (COVID-19) infection: Case based review. Egypt. Rheumatol. 2022 44 3 275 278 10.1016/j.ejr.2022.03.001 37521095
    [Google Scholar]
  33. Berdal G. Halvorsen S. van der Heijde D. Mowe M. Dagfinrud H. Restrictive pulmonary function is more prevalent in patients with ankylosing spondylitis than in matched population controls and is associated with impaired spinal mobility: A comparative study. Arthritis Res. Ther. 2012 14 1 R19 10.1186/ar3699 22277377
    [Google Scholar]
  34. Dincer U. Cakar E. Kiralp M.Z. Bozkanat E. Kilac H. Dursun H. The pulmonary involvement in rheumatic diseases: pulmonary effects of ankylosing spondylitis and its impact on functionality and quality of life. Tohoku J. Exp. Med. 2007 212 4 423 430 10.1620/tjem.212.423 17660708
    [Google Scholar]
  35. El Maghraoui A. Chaouir S. Abid A. Bezza A. Tabache F. Achemlal L. Abouzahir A. Ghafir D. Ohayon V. Archane M.I. Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin. Rheumatol. 2004 23 2 123 128 10.1007/s10067‑003‑0845‑8 15045626
    [Google Scholar]
  36. Sampaio-Barros P.D. Cerqueira E.M.F.P. Rezende S.M. Maeda L. Conde R.A. Zanardi V.A. Bértolo M.B. de Menezes Neto J.R. Samara A.M. Pulmonary involvement in ankylosing spondylitis. Clin. Rheumatol. 2007 26 2 225 230 10.1007/s10067‑006‑0286‑2 16572281
    [Google Scholar]
  37. Ibinaiye P.O. Salawu F. Pulmonary manifestations of ankylosing spondylitis treated as pulmonary tuberculosis: A case report and review of literature. Niger. Postgrad. Med. J. 2009 16 4 274 276 10.4103/1117‑1936.181413 20037624
    [Google Scholar]
  38. Rosenow E. Strimlan C.V. Muhm J.R. Ferguson R.H. Pleuropulmonary manifestations of ankylosing spondylitis. Mayo Clin. Proc. 1977 52 10 641 649 909316
    [Google Scholar]
  39. Lee C.C. Lee S.H. Chang I.J. Lu T.C. Yuan A. Chang T.A. Tsai K.C. Chen W.J. Spontaneous pneumothorax associated with ankylosing spondylitis. Rheumatology 2005 44 12 1538 1541 10.1093/rheumatology/kei077 16105907
    [Google Scholar]
  40. Rumancik W.M. Firooznia H. Davis M.S. Jr Leitman B.S. Golimbu C. Rafii M. McCauley D.I. Fibrobullous disease of the upper lobes: An extraskeletal manifestation of ankylosing spondylitis. J. Comput. Tomogr. 1984 8 3 225 229 10.1016/0149‑936X(84)90066‑3 6744925
    [Google Scholar]
  41. Cohen A.A. Natelson E.A. Fechner R.E. Fibrosing interstitial pneumonitis in ankylosing spondylitis. Chest 1971 59 4 369 371 10.1378/chest.59.4.369 5551581
    [Google Scholar]
  42. Campbell A.H. MacDonald C.B. Upper lobe fibrosis associated with ankylosing spondylitis. Br. J. Dis. Chest 1965 59 2 90 101 10.1016/S0007‑0971(65)80017‑1 14283439
    [Google Scholar]
  43. Uffmann M. Kiener H.P. Bankier A.A. Baldt M.M. Zontsich T. Herold C.J. Lung manifestation in asymptomatic patients with primary Sjögren syndrome: Assessment with high resolution CT and pulmonary function tests. J. Thorac. Imaging 2001 16 4 282 289 10.1097/00005382‑200110000‑00009 11685093
    [Google Scholar]
  44. Wang Y. Hou Z. Qiu M. Ye Q. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. J. Thorac. Dis. 2018 10 4 2108 2117 10.21037/jtd.2018.03.120 29850114
    [Google Scholar]
  45. Lohrmann C. Uhl M. Warnatz K. Ghanem N. Kotter E. Schaefer O. Langer M. High-resolution CT imaging of the lung for patients with primary Sjögren’s syndrome. Eur. J. Radiol. 2004 52 2 137 143 10.1016/j.ejrad.2004.01.006 15489070
    [Google Scholar]
  46. Deheinzelin D. Capelozzi V.L. Kairalla R.A. Barbas Filho J.V. Saldiva P.H. de Carvalho C.R. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am. J. Respir. Crit. Care Med. 1996 154 3 794 799 10.1164/ajrccm.154.3.8810621 8810621
    [Google Scholar]
  47. Dong X. Zhou J. Guo X. Li Y. Xu Y. Fu Q. Lu Y. Zheng Y. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin. Rheumatol. 2018 37 11 2981 2988 10.1007/s10067‑018‑4289‑6 30242640
    [Google Scholar]
  48. Liebow A.A. Carrington C.B. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med. Clin. North Am. 1973 57 3 809 843 10.1016/S0025‑7125(16)32278‑7 4540729
    [Google Scholar]
  49. Ramos-Casals M. Brito-Zerón P. Seror R. Bootsma H. Bowman S.J. Dörner T. Gottenberg J.E. Mariette X. Theander E. Bombardieri S. De Vita S. Mandl T. Ng W.F. Kruize A. Tzioufas A. Vitali C. EULAR Sjögren Syndrome Task Force Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 2015 54 12 2230 2238 10.1093/rheumatology/kev200 26231345
    [Google Scholar]
  50. Myers J.L. Colby T.V. Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin. Chest Med. 1993 14 4 611 622 10.1016/S0272‑5231(21)00925‑4 8313666
    [Google Scholar]
  51. Müller N.L. White D.A. Jiang H. Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br. J. Cancer 2004 91 S2 Suppl. 2 S24 S30 10.1038/sj.bjc.6602064 15340375
    [Google Scholar]
  52. Atzeni F. Boiardi L. Sallì S. Benucci M. Sarzi-Puttini P. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev. Clin. Immunol. 2013 9 7 649 657 10.1586/1744666X.2013.811173 23899235
    [Google Scholar]
  53. Pavy S. Constantin A. Pham T. Gossec L. Maillefert J.F. Cantagrel A. Combe B. Flipo R.M. Goupille P. Le Loët X. Mariette X. Puéchal X. Schaeverbeke T. Sibilia J. Tebib J. Wendling D. Dougados M. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006 73 4 388 395 10.1016/j.jbspin.2006.01.007 16626993
    [Google Scholar]
  54. Kremer J.M. Alarcón G.S. Weinblatt M.E. Kaymakcian M.V. Macaluso M. Cannon G.W. Palmer W.R. Sundy J.S. St Clair E.W. Alexander R.W. Smith G.J. Axiotis C.A. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: A multicenter study with literature review. Arthritis Rheum. 1997 40 10 1829 1837 10.1002/art.1780401016 9336418
    [Google Scholar]
  55. Sieiro Santos C. Álvarez Castro C. Moriano Morales C. Díez Álvarez E. Anti-TNF-α-induced lupus syndrome. Z. Rheumatol. 2021 80 5 481 486 10.1007/s00393‑021‑00983‑8 33709168
    [Google Scholar]
  56. Skalkou A. Pelechas E. Voulgari P.V. Drosos A.A. TNF-induced Lupus. A case-based review. Curr. Rheumatol. Rev. 2022 18 1 72 82 10.2174/1573397117666211102094330 34727862
    [Google Scholar]
  57. Shovman O. Tamar S. Amital H. Watad A. Shoenfeld Y. Diverse patterns of anti-TNF-α-induced lupus: Case series and review of the literature. Clin. Rheumatol. 2018 37 2 563 568 10.1007/s10067‑017‑3884‑2 29063464
    [Google Scholar]
  58. Perez-Alvarez R. Perez-de-Lis M. Diaz-Lagares C. Pego-Reigosa J.M. Retamozo S. Bove A. Brito-Zeron P. Bosch X. Ramos-Casals M. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin. Arthritis Rheum. 2011 41 2 256 264 10.1016/j.semarthrit.2010.11.002 21277618
    [Google Scholar]
  59. Nakashita T. Ando K. Kaneko N. Takahashi K. Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open 2014 4 8 e005615 10.1136/bmjopen‑2014‑005615 25125479
    [Google Scholar]
  60. Koo B.S. Hong S. Kim Y.J. Kim Y.G. Lee C.K. Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J. Intern. Med. 2015 30 1 104 109 10.3904/kjim.2015.30.1.104 25589842
    [Google Scholar]
/content/journals/crr/10.2174/0115733971315532240920065136
Loading
Sjögren’s  Syndrome  and  Ankylosing   Spondylitis   Association:   A Case-Based Review
Bentham Science Publishers ; https://doi.org/10.2174/0115733971315532240920065136
/content/journals/crr/10.2174/0115733971315532240920065136
/content/journals/crr/10.2174/0115733971315532240920065136
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: ankylosing spondylitis ; Interstitial lung disease ; spondyloarthritis ; Sjögren’s syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test